论文部分内容阅读
目的:探讨β2-肾上腺素能受体兴奋剂利托君期待治疗前置胎盘的效果。方法:将100例未足月前置胎盘患者随机分为两组,治疗组和对照组各50例。所有患者住院后予卧床休息,并严密监测生命体征及阴道出血情况,监护胎儿宫内情况,贫血者予纠正贫血。在此基础上治疗组给予利托君治疗,对照组给予硫酸镁治疗。比较应用利托君和硫酸镁后阴道出血情况、显效时间、延长孕周时间及新生儿情况。结果:经利托君治疗后,孕妇阴道出血情况明显好转,孕期延长、新生儿出生体重和1min Apgar评分与对照组比较差异均有统计学意义(P<0.05)。结论:利托君用于前置胎盘期待治疗效果显著、安全,可作为前置胎盘抑制宫缩的首选药物。
Objective: To investigate the effect of beta2-adrenergic receptor agonist Rituxan on the treatment of placenta previa. Methods: One hundred patients who had not been given placenta previa were randomly divided into two groups, the treatment group and the control group each with 50 cases. All patients were hospitalized to bed rest, and close monitoring of vital signs and vaginal bleeding, monitoring of intrauterine conditions, anemia to correct anemia. On this basis, the treatment group was treated with ritodrine, while the control group was given magnesium sulfate. Compare the application of Rituximab and magnesium sulfate after vaginal bleeding, markedly effective, extended gestational age and neonatal conditions. Results: After treatment with ritodrine, the situation of vaginal bleeding in pregnant women was improved significantly, the pregnancy duration was prolonged, the newborn birth weight and Apgar score at 1 minute were significantly different from those in control group (P <0.05). Conclusion: Rituximab is a promising and safe treatment for placenta previa. It can be used as the first choice for inhibiting placenta previa.